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Abstract
Background: Our objective was to determine the frequency and determinants of presentation to care with
advanced HIV disease in patients who discover their HIV diagnosis at this stage as well as those with delayed
presentation to care after HIV diagnosis in earlier stages.
Methods: We collected data on 1,819 HIV-infected patients in Brussels (Belgium) and Northern France from
January 1997 to December 2007. “Advanced HIV disease” was defined as CD4 count <200/mm
3 or clinically-defined
AIDS at study inclusion and was stratified into two groups: (a) late testing, defined as presentation to care with
advanced HIV disease and HIV diagnosis ≤6 months before initiation of HIV care; and (b) delayed presentation to
care, defined as presentation to care with advanced HIV disease and HIV diagnosis >6 months before initiation of
HIV care. We used multinomial logistic regression to determine the factors associated with delayed presentation to
care and late testing.
Results: Of the 570 patients initiating care with advanced HIV disease, 475 (83.3%) were tested late and 95 (16.7%)
had delayed presentation to care. Risk factors for delayed presentation to care were: age 30-50 years, injection
drug use, and follow-up in Brussels. Risk factors for late testing were: sub-Saharan African origin, male gender, and
older age. HIV transmission through heterosexual contact was associated with an increased risk of both delayed
presentation to care and late testing. Patients who initiated HIV care in 2003-2007 were less likely to have been
tested late or to have a delayed presentation to care than patients who initiated care before 2003.
Conclusion: A considerable proportion of HIV-infected patients present to care with advanced HIV disease. Late
testing, rather than a delay in initiating care after earlier HIV testing, is the main determinant of presentation to
care with advanced HIV disease. The factors associated with delay presentation to care differ from those associated
with late testing. Different strategies should be developed to optimize early access to care in these two groups.
Background
Despite the availability and known benefits of com-
bined antiretroviral therapy (cART), a considerable
proportion of HIV-infected patients have experienced
significant immunodeficiency or disease progression
before they present to care [1-7]. These patients often
have poor prognoses [8], because cART reduces HIV
RNA and mortality more effectively when it is initiated
early [9-13]. In a recent study conducted in France,
six-month mortality among patients who initiated care
with advanced HIV disease, defined as CD4 count
<200/mm
3 and/or AIDS, was 13.6 higher than among
patients who initiated care early [2]. Mortality rates
remained higher among these patients four years after
enrolment. In addition to improving outcomes at the indi-
vidual level, studies have shown that effective prevention
counseling and early cART initiation can also reduce the
clinical and financial burden of HIV at the population
level by reducing HIV transmission rates [14-18].
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advanced HIV disease can be stratified into two groups:
(i) patients who discover their HIV infection with an
advanced HIV disease and thus initiate care late; and
(ii) patients who discover their HIV infection earlier but
delay initiating HIV care. Although several recent stu-
dies have evaluated the factors associated with presenta-
tion to care with advanced HIV disease [1-7], few
studies have assessed the factors associated with presen-
tation to care at this stage, by delay from first positive
HIV test to presentation to care. The risk factors for
presentation to care with advanced HIV disease may be
different in these two groups.
The objective of this study was to determine the fre-
quency and characteristics associated with late HIV test-
ing with an advanced HIV disease and earlier HIV
testing followed by delayed presentation to care with an
advanced HIV disease among HIV-infected patients in
Brussels (Belgium) and Northern France.
Methods
Patients
The Nord Pas-de-Calais region, one of 22 administrative
regions in France, has a population of four million. Its
cumulative incidence of AIDS is one of the lowest in
France, at 299.4 cases per million inhabitants [19]. The
Brussels administrative region is one of three in Belgium
and has a population of one million. Its cumulative inci-
dence of AIDS is one of the highest in Belgium, at 1,525
cases per million inhabitants [20].
We collected data on HIV-infected patients who
received care at hospitals in Tourcoing, Valenciennes,
Lens, Dunkerque, and Boulogne (Nord-Pas-de-Calais),
as well as the Saint-Luc University Hospital in Brussels
(Belgium) from January 1997 to December 2007. The
Tourcoing AIDS Reference Centre of Lille University
Teaching Hospital provides primary and subspecialty
care to HIV-infected patients in the Lille-Roubaix-Tour-
coing metropolitan area, the main urban area of the
Nord Pas-de-Calais region. The Tourcoing AIDS Refer-
ence Centre has been described elsewhere in detail [21].
The hospitals in the smaller cities of Valenciennes, Lens,
Dunkerque, and Boulogne also provide HIV care. Saint-
Luc University Hospital [22] is one of two main hospi-
tals that provide HIV in the Brussels metropolitan area.
Patients were eligible for the study if they received a
confirmatory Western blot, were aged ≥18 years, had
initiated care in one of the study centres, and gave
informed consent to be included in the study. We con-
sidered that a patient had initiated care if he attended
the study centers at least twice. We used standard ques-
tionnaires to collect complete prospective demographic,
clinical, and laboratory data, as well as drug prescription
information at the Tourcoing AIDS Reference Centre.
Trained technicians in Tourcoing collected follow-up
data at each outpatient visit and hospitalization, or at
least every 6 months. Follow-up data were entered into
standard computer records. In the other study centres,
baseline and follow-up data were extracted retrospec-
tively from patient charts, using the same standardized
questionnaires as those used in Tourcoing.
Definitions
Presentation with “advanced HIV disease” [7] was
defined as initial presentation to care (i.e., the first clini-
cal visit for HIV care) with CD4 count <200/mm
3 or
clinically-defined AIDS. Presentation with “advanced
HIV disease was stratified into two groups, according to
the delay from the date of first positive HIV test result
to the date of presentation to HIV care: (a) “late test-
ing,” defined as presentation with “advanced HIV dis-
ease” and HIV diagnosis ≤6 months before initial
presentation to care; and (b) “delayed presentation to
care,” defined as presentation with “advanced HIV dis-
ease” and HIV diagnosis >6 months before initial pre-
sentation to care. In sensitivity analysis, we varied the
CD4 count threshold at which patients presented to
care with CD4 cell counts <50/mm
3 to 350/mm
3.
Variables
We assessed the factors associated with “late testing”
and “delayed presentation to care” a n dc o m p a r e dt h e m
to the factors associated with “earlier presentation,”
defined as initiation of HIV care at CD4 counts >200/
mm
3 and no AIDS.
We evaluated the demographic, clinical, biological and
social characteristics of the patients included in the
study. Demographic data included age at enrolment
(<30 years, 30-39, 40-49 and >50), gender, origin (sub-
Saharan African immigrant or not) and HIV transmis-
sion category. Gender and origin were stratified into
four groups: non-immigrant women, non-immigrant
men, immigrant men and immigrant women [2]. We
stratified HIV transmission into four categories, in hier-
archical order: injection drug users (IDU), men who
have sex with men (MSM), heterosexual contact, and
other. Patients who belonged to more than one trans-
mission group were placed in the first relevant category
of the hierarchy. AIDS-defining diseases at initial pre-
sentation to care were identified using the Expanded
European AIDS definition [23]. We created three cate-
gories for period of inclusion: 1997-1999, 2000-2002,
and 2003-2007.
Statistical Analysis
We determined the proportion and characteristics of
patients in the “delayed presentation to care” and “late
testing” groups and compared them to patients who
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the chi 2 test to compare proportions and Wilcoxon’s
test to compare medians. In order to identify the factors
that were independently associated with “delayed pre-
sentation to care” and “late testing,” we entered the vari-
ables found to be associated with these outcomes in
univariate analysis (p-value < 0.20) into a multinomial
logistic regression model. In multivariate analysis, asso-
ciations with p-values < 0.05 in Wald’st e s tm o d e lw e r e
considered to be significant. We also evaluated the
interaction between study country and the variables
associated with “delayed presentation to care” and “late
testing” in multivariate analysis. The significance level
was set to 5%. All statistical analyses were performed
using SPSS version 13.0 (SPSS Inc., Chicago. IL).
Results
We collected data on 1,819 patients who were followed
in Northern France and Brussels from January 1997 to
December 2007. The initial characteristics of patients in
Northern France and Brussels were the following: med-
ian age, 35 years (interquartile range [IQR], 28-43) and
36 years (IQR, 30-43; p = 0.07); proportion of men,
70.6% (860) and 56.2% (338; p < 0.0001); proportion of
MSM, 44.9% (541) and 28.3% (156; p < 0.0001); propor-
tion of IDU, 3.4% (41) and 1.8% (10; p < 0.0001); pro-
portion of sub-Saharan African immigrants, 21.8% (265)
and 53.1% (319; p < 0.0001); proportion of patients who
initiated care in 2003-2007, 43.9% (535) and 54.9%
(330), proportion of patients with AIDS-defining dis-
eases at enrolment, 16.0% (195) and 11.1% (67; p =
0.005); and median CD4 count at inclusion, 353/mm
3
(IQR, 172-548) and 305/mm
3 (IQR, 165-485; p = 0.006)
(Table 1).
The proportion of patients who presented to care with
advanced HIV disease was 31.3% and did not differ sig-
nificantly between countries (Table 2). The numbers of
patients who presented to care with AIDS or CD4
counts <50/mm
3, and <350/mm
3 were 323 (17.6%), and
957(52.3%) (Table 2).
Table 3 shows the frequency of “late testing” and
“delayed presentation to care” stratified by country.”
Nearly 17% of patients with advanced HIV disease were
diagnosed earlier but delayed initiating HIV care and
83% were diagnosed late. Thirty nine of 95 (41.1%)
patients with delayed presentation to care and 222 of
475 (46.7%) patients with late testing had an AIDS-
defining illness at their initial presentation to care. Med-
ian time from HIV diagnosis to initial presentation to
HIV care in the “delayed presentation to care” group
w a s5 5m o n t h s( I Q R ,2 3 - 8 8 ) .I nt h i sg r o u p ,8 5p a t i e n t s
(89.5%) tested positive for HIV >1 year before enrolling
in the study. The frequency of “late testing” did not dif-
fer significantly between Northern France and Belgium,
regardless of the definition of “late presentation” used.
In contrast, the rate of “delayed presentation to care”
did differ significantly between countries: “delayed pre-
sentation to care” was twice as frequent in Brussels than
in Northern France (Table 3).
Table 4 shows the results of multinomial logistic
regression analysis. The reference category was presen-
tation to care without advanced HIV disease. Patients
aged 30-40 years (odds ratio [OR], 3.28; 95% confidence
interval [CI], 1.68-6.41) and 40-50 years (OR, 5.44; 95%
CI, 2.69-11.02) were at higher risk of “delayed presenta-
tion to care” compared to patients aged <30 years. Com-
p a r e dt oM S M ,p a t i e n t si nt h eh e t e r o s e x u a lc o n t a c t
transmission category (OR, 1.90; 95% CI, 1.14-3.21) and
IDU (OR, 3.03; 95% CI, 1.14-9.53) were more likely to
have tested earlier and presented to care with advanced
HIV disease. Study inclusion in 1997-1999 was asso-
ciated with “delayed presentation to care” compared to
inclusion in 2003-2007 (OR, 3.20; 95% CI, 1.88-5.43).
Patients in Brussels were also more likely to have tested
early and presented to care with advanced HIV disease
Table 1 Demographic and clinical characteristics of HIV-
infected patients in 6 clinical centres in Northern France
and Brussels: January 1997 to December 2007
Characteristics Northern
France
(n = 1218)
Brussels,
Belgium
(n = 601)
p-value
Age, years
Median 35 36 0.07
25
th percentile 28 30
75
th percentile 43 43
Gender <0.0001
Male 860 (70.6%) 338 (56.2%)
Female 358 (29.4%) 263 (43.8%)
HIV transmission category <0.0001
Men who have sex with men 541 (44.9%) 156 (28.3%)
Injection drug use 41 (3.4%) 10 (1.8%)
Heterosexual contact 622 (51.7%) 385 (69.9%)
Sub-Saharan African
immigrant
<0.0001
Yes 265 (21.8%) 319 (53.1%)
No 953 (78.2%) 282 (46.9%)
Period at enrolment <0.0001
1997-1999 337 (27.7%) 124 (20.6%)
2000-2002 346 (28.4%) 147 (24.5%)
2003-2007 535 (43.9%) 330 (54.9%)
AIDS-defining disease at
enrolment
195 (16.0%) 67 (11.1%) 0.005
Baseline CD4 count,/mm
3
Median 353 305 0.006
25
th percentile 172 165
75
th percentile 548 485
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CI, 1.51-3.75).
Rates of “late testing” increased as age increased from
30-40 years (OR, 2.00 compared to <30 years) to ≥50
years (OR, 4.07 compared to <30 years; p < 0.0001).
Compared to non-immigrant women, immigrant women
(OR, 2.23; 95% CI, 1.48-2.70), non-immigrant men (OR,
1.86; 95% CI, 1.23-2.80), and immigrant men (OR, 2.17;
95% CI, 2.03-4.00) were more likely to be diagnosed
l a t e .C o m p a r e dt oM S M ,p a t i e n t si nt h eh e t e r o s e x u a l
c o n t a c tt r a n s m i s s i o nc a t e g o r yw e r em o r el i k e l yt ob e
diagnosed late (OR, 1.56; 95% CI, 1.13-2.14). Compared
to patients who enrolled in the study in 2003-2007,
patients who enrolled in 2000-2002 (OR, 1.58; 95% CI,
1.21-2.06) and 1997-1999 (OR, 1.42; 95% CI, 1.07-1.88)
were more likely to have been diagnosed late.
Discussion
We estimated the frequency of patients who presented
to care with advanced HIV disease among 1,819 HIV-
infected patients in the Nord-Pas-de-Calais region
(France) and Brussels (Belgium) from January 1997 to
December 2007. Moreover, within patients with
advanced HIV disease we determined the frequency of
“late testing” (i.e.; HIV diagnosis ≤6m o n t h sb e f o r e
initial presentation to care) and “delayed presentation to
care” (i.e.; HIV diagnosis >6 months before initial pre-
sentation to care). Finally, we assessed the potential risk
factors associated with “delayed presentation to care"/
"late testing” and presentation to care with advanced
HIV disease. Of the 570 patients (31.3%) who presented
to care with advanced HIV disease, 95 (16.7%) were
diagnosed early but delayed initiating HIV care for >6
months, and 475 (83.3%) were diagnosed late. Older
patients, sub-Saharan African immigrants, non-immi-
grant men and patients who enrolled in the study
between 1997 and 2002 were more likely to be diag-
nosed late. Risk factors for “delayed presentation to
care” and presentation to care with advanced HIV dis-
ease were: age 30-49 years, HIV transmission through
heterosexual contact or injection drug use, enrolment in
the study between 1997 and 1999, and follow-up in
Brussels.
There are multiple definitions of “late presentation” or
“delayed HIV diagnosis” in the medical literature.
Recently, The UK Collaborative HIV Cohort (UK CHIC)
Steering Committee defined presentation at a stage
when there is a substantial risk of death (i.e., CD4
counts <200/mm
3 or clinically-defined AIDS) as presen-
tation with “advanced HIV disease” and presentation
with a CD4 cell count below 350/mm
3,r e s u l t i n gi na
delay in treatment initiation, as “late presentation”[7]. In
this analysis we focused on patients with advanced HIV
diagnosis and showed that 31.3% of patients initiated
care at CD4 counts <200/mm
3 or clinically-defined
AIDS. This proportion was found to be similar in
Northern France and Belgium, and is comparable to
estimates from several recent European studies that
used the same definition for “late presentation.” In these
studies, rates of “late presentation” ranged from 27% to
59% [1-7]. In our study, 16.7% of those with advanced
HIV disease were aware of their HIV status but delayed
initiating care for >6 months. Thus, late testing, rather
than delay in initiating care after testing HIV positive, is
the main determinant of presentation to care with
advanced HIV disease. Of note, the proportion of
patients who initiated care with an AIDS-defining event
was comparable in patients with late testing and those
Table 2 The proportion of patients who presented to care with AIDS or CD4 counts <50/mm
3, < 200/mm
3 and <350/
mm
3 among HIV-infected patients in Northern France and Brussels: January 1997 to December 2007
Prevalence
Presentation to care Total
n = 1819
Northern France
n = 1218
Brussels
n = 601
p-value
CD4 count <50/μl or AIDS 323 (17.6%) 221 (18.1%) 102 (17.0%) 0.31
CD4 count <200/μl or AIDS* 570 (31.3%) 373 (30.6%) 197 (32.8%) 0.18
CD4 count <350/μl or AIDS 957 (52.9%) 614 (50.4%) 343 (57.1%) 0.21
*Advanced HIV disease.
Table 3 Proportion of “delayed presentation to care” and “late testing” among HIV-infected patients who present to
care late in Northern France and Brussels: January 1997 to December 2007
Total
n/N (%)
Northern France
n/N (%)
Brussels, Belgium
n/N (%)
p-value
Presentation to care with advanced HIV disease*and
HIV diagnosis >6 months before initiation of care
95/570 (16.7) 44/373 (11.8) 51/197 (25.9) 0.0003
Presentation to care with advanced HIV disease*and
HIV diagnosis ≤6 months before initiation of care
475/570 (83.3) 329/373 (88.2) 146/197 (74.1) 0.18
* CD4 < 200 cells/μl or AIDS.
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testing is also the main reason of presentation to care
with AIDS. Few studies, especially in Europe, have
focused their analysis on the group of patients delaying
HIV care. In the Italian Cohort Naive Antiretrovirals,
26.1% of all HIV infected patients delayed initiating care
for >6 months after HIV diagnosis, and these patients
represented 26.1% of patients with <200 CD4 cells/mm
3
or clinically defined AIDS upon enrolment [24]. This
estimate, using the same definition, is higher than the
results from our study in Northern France (11.8% with
advanced HIV disease had delayed initiating care) but
close to those in the Belgium clinical cohort (25.9% with
advanced HIV disease had delayed initiating care)
Consistent with previous studies, our findings show
that older patients, heterosexuals, sub-Saharan African
immigrants, non-immigrant men and patients who
initiated care between 1997 and 2002 were more likely
to be diagnosed late with advanced HIV disease [25-32].
The risk of “late testing” increased with age, from an
OR of 2.00 among patients aged 30-40 years to 4.07
among patients aged ≥50 years, compared to patients
aged <30 years. Previous studies have estimated that the
risk of “late testing” in older age groups ranges from 3
to 6.5 [2,11,24,33-36]. A recent review evaluated the
psychosocial factors associated with HIV testing in high-
income countries. The authors concluded that indivi-
duals generally get tested for HIV for the first time
when they perceive that they have been at risk [37].
Older individuals and heterosexuals may not feel at risk
of HIV infection. Our finding that sub-Saharan African
immigrants are at risk of presentation with advanced
HIV disease corroborates previous reports that this
group faces obstacles to HIV testing. A British study
that investigated HIV testing practices among African
immigrant communities found that although general
HIV awareness was high, perception of individual risk
was poor [38]. Furthermore, they found that cultural
norms and stigma in immigrant communities often con-
tributed to late presentation and remained a major bar-
rier to HIV testing [11]. Immigrants usually present to
care with immediate and specific needs, and the idea of
getting tested for a disease before having symptoms,
even when the risk of infection is high, is often rejected.
Our finding that a large proportion of late HIV diag-
noses were among non-immigrant men was also
Table 4 Multivariate multinomial logistic regression analysis: Factors associated with “delayed presentation to care”
and “late testing” among HIV-infected patients in Northern France and Brussels, from January 1997 to December
2007
“delayed presentation to care” with advanced HIV
disease* despite earlier HIV testing
“Late testing” and presentation to care with
advanced HIV disease*
n total n (%) OR 95% CI n total n (%) OR 95% CI
Age, years
<30 454 12 (2.6) 1.00 529 87 (16.4) 1.00
30-39 500 43 (8.6) 3.28 1.68-6.41 635 178 (28.0) 2.00 1.82-2.70
40-49 256 31 (12.1) 5.44 2.69-11.02 344 119 (34.6) 2.85 2.03-4.00
≥50 134 9 (6.7) 2.48 0.97-6.35 216 91 (42.1) 4.07 2.76-6.02
Sex and immigrant status
Non-immigrant women 235 52 (22.1) 1.00
Immigrant women 348 113 (32.5) 2.23 1.48-2.70
Non-immigrant men 980 254 (25.9) 1.86 1.23-2.80
Immigrant men 161 56 (34.8) 2.17 2.03-4.00
HIV transmission category
Men who have sex with men 550 23 (4.2) 1.00 674 147 (21.8) 1.00
Injection drug use 43 4 (9.3) 3.03 1.14-9.53 47 8 (17.0) 0.79 0.34-1.84
Heterosexual contact 709 63 (8.9) 1.90 1.14-3.21 944 298 (31.6) 1.56 1.13-2.14
Study inclusion period
2003-2007 637 32 (4.8) 1.00 833 205 (24.6) 1.00
2000-2002 332 26 (7.6) 1.76 0.99-3.14 467 151 (32.3) 1.58 1.21-2.06
1997-1999 333 37 (10.8) 3.20 1.88-5.43 424 119 (28.1) 1.42 1.07-1.88
Country of follow-up
France 889 44 (4.9) 1.00
Belgium 455 51 (11.2) 2.34 1.51-3.75
Reference category is presentation to care without advanced HIV disease.
* CD4 < 200 cells/μl or AIDS.
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systematically tested for HIV during pregnancy, men are
not generally offered HIV tests on a routine basis.
Although several studies have investigated the factors
associated with “late presentation” and “late testing,” few
studies have evaluated the characteristics of patients
who get diagnosed with HIV early but delay presenting
to care. We show that the risk factors for “delayed pre-
sentation to care” and “late testing” among patients who
present with advanced HIV disease are different. First,
we found that IDUs are more likely to test early and
delay presenting to care. This result is consistent with
previous studies [24] and demonstrates that IDU present
with advanced HIV disease not because they are tested
for HIV infrequently, but rather because they are not
efficiently linked to care. In fact, IDU regularly receive
HIV tests in specialized drug treatment centres. More-
over, because they are considered to be at high risk of
HIV infection, physicians frequently offer them HIV
tests during regular clinic visits. Despite their tendency
to be diagnosed early, however, IDU are difficult to
enroll and retain in care [21,25,39-43].
Second, although we found that rates of “late testing”
increase with age, we did not find the same trend in the
“delayed presentation to care” group. Patients aged 30-
49 years were at increased risk of “delayed presentation
to care” and presentation to care with advanced HIV
disease compared to patients aged <30 years, but
patients aged >50 years were not. Unlike patients aged
>50 years, those aged 30-49 years may seek an HIV test
because of a perceived risk, but then delay presenting to
care to avoid HIV-related stigma. The number of
patients >50 years in our cohort was small, however, so
any interpretation of this result should be made with
caution. Finally, we found that patients who were fol-
lowed in Brussels were twice more likely to be diag-
nosed early and delay presenting to care than patients
who were followed in Northern France. Of note, as sta-
ted above, the proportion of patients diagnosed early
with presentation to care at advanced HIV disease in
Brussels was close to estimates in the Italian Cohort
Naive Antiretrovirals [24]. This finding may be related
to different testing and counselling services and/or link-
age to care services in different countries. Girardi et al.
for example have shown in their study that having no
counselling at the time of first positive test were asso-
ciated with a higher probability of delayed presentation
to care[24], but unfortunately this information was not
available in our datasets. Differences may be also
explained by differences in patient characteristics. Our
f i n d i n g sm a yb ef o re x a m p l ee x p l a i n e db yt h eh i g h e r
proportion of sub-Saharan African immigrants in Brus-
sels when compared to Northern France. In multinomial
logistic regression analysis, we adjusted our results for
patient characteristics, including patient origin, but we
may not have adjusted our results for all potential con-
founders. Differences between our study and the Italian
study maybe also related to difference in the time period
during which the analysis was conducted. As seen in
previous studies, in our study rates of “late testing” and
“delayed presentation to care” decreased overtime
[24,33]. This trend is likely related to the increasing
availability of more effective and less toxic cART regi-
mens, as well as improvements in HIV care.
Our study has several limitations. First, our results
cannot be generalized to locations outside of Northern
France and Brussels, because the risk factors associated
with “delayed presentation to care” and “late testing”
may depend on population characteristics and local HIV
screening practices. Although most of our results are
consistent with previous studies, some risk factors for
“delayed presentation to care” and “late testing” may
depend on geography: patients in Brussels were more
likely to be diagnosed early and delay presentation care
compared to patients in Northern France. Second,
although most data were collected prospectively, the
study was designed after data collection had ended. We
were therefore unable to assess the impact of variables
such as incarceration, homelessness, illegal immigrant
status, unemployment status, HIV testing history, psy-
chological condition, counselling and community sup-
port on outcomes. These variables might influence rates
of “delayed presentation to care” and “late testing.”
Third, the delay from initial HIV diagnosis to initial pre-
sentation to care, which was used to differentiate
patients in the “late testing” and “delayed presentation
to care” groups, was often self-reported and thus subject
to recall bias. Finally, we may not have had enough sta-
tistical power to evaluate some of the risk factors asso-
ciated with “delayed presentation to care”, because the
number of patients who were diagnosed early and
delayed presentation to care was small.
Conclusion
Despite the wide availability of cART in Western
Europe, access to care with advanced HIV disease
remains common in France and Belgium, with almost
one third of HIV-infected patients initiating care at CD4
counts <200/mm
3 and/or AIDS in recent years. This
study shows that, although late HIV testing is the most
frequent cause of delayed presentation to care, low rates
of linkage to care also lead to late presentation. In our
study, 17% of patients delayed initiating care after being
diagnosed with HIV. Because the factors associated with
“delayed presentation to care” differ from those asso-
ciated with “late testing,” different strategies should be
developed to optimize early initiation of HIV care in
each group. One method for increasing the proportion
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screening practices. In France, the Haute Autorité de
Santé [44,45] recently recommended one-time universal,
routine, voluntary HIV screening in the general popula-
tion, and more frequent screening in higher-risk groups.
General practitioners in particular should be encouraged
to provide HIV tests on a routine basis, in order to
improve access to care at the individual level and limit
the spread of infection at the population level [46,47].
Interventions to improve linkage to care should be
implemented alongside HIV screening strategies, parti-
cularly in marginalized groups such as IDU, who tend
to be diagnosed early but to delay presentation to care.
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